# Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

> **NCT04503668** · PHASE3 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 62 (actual)

## Conditions studied

- Gynecologic Cancer

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Dexamethasone
- **DRUG:** Neurokinin-1 Receptor Antagonist (NK1-RA)
- **DRUG:** Olanzapine
- **DRUG:** Compazine

## Key facts

- **NCT ID:** NCT04503668
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-28
- **Primary completion:** 2024-01-03
- **Final completion:** 2024-03-11
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Lack of Patient Population
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503668, "Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04503668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*